

**ONLINE APPENDIX**

**TABLE I: Clinical data of Patients with Macular Hole**

<b>Age/ Sex</b>	<b>Past history</b>	<b>Treatment for Systemic Disorder</b>	<b>Other Ocular Dis- order</b>	<b>Duration of Vision Loss</b>	<b>Eye Affected</b>	<b>Macular Hole Grade</b>	<b>Treatment</b>	<b>Baseline Investigations</b>
61/F	G <sub>6</sub> PD Deficiency	T. Olvo T.Nayapred T. Oplex	NIL	1 Month	OD	FTMH	NIL	RBS- 103 BU- 32 SCR- 1.07
55/M	NIL	NIL	NIL	2 Years	OD	FTMH	NIL	RBS- 133
31/M	HT	NIL	NIL	3 Months	OD	FTMH	NIL	RBS- 100
54/F	Raised BS levels	T. Glyciphage 500mg T. Losar 50	NIL	6 months	OU	FTMH	NIL	RBS- 233
63/M	NIL	NIL	NIL	6 months	OS	FTMH	NIL	RBS- 115 BU- 15 SCR- 0.9
65/F	Trigemina l neuralgia	T. tegretal CR T. Baclofen	NIL	4 months	OS	FTMH	NIL	RBS- 138 BU- 23 SCR- 0.8
67/M				1 month	OD			
57/M	NIL	NIL	Nil	2 years	OU	OD= FTMH OS= Lamellar MH	NIL	RBS 108

FTMH, full thickness macular hole; PVD, posterior vitreous detachment; CNVM, choroidal neovascular membrane; ERM, epiretinal membrane; RBS, random blood sugar; SCR, serum creatinine; BU, blood urea.

**TABLE II: Clinical Data of patients with PDR**

Age/ Sex	Past Treat- ment History	Duration of Diabetes (yrs)	Type	DR Quadra nt	Vit Haem	Retinal Detach- ment	Other features	Eye Operated	Treatment	Baseline Investigat ions	Associated Disorder
43/ F	None	16	1	4	+	TRD	OU=FVP	OU	T losar, T Femolid,	RBS-322, BU-22, SCR-0.8	Hypercholeste rolemia
61/ F	None	29	1	4	-	CRD	OD= 360° NVI FVP	OD	T Atenolol, T Glyco phage, T Lipitor, T Pioglitozone	RBS 300, BU-69, SCR-2.5	HT, Hypercholeste rolemia, CKD Stage IV
54/ M	Laser, Anti VEGF	3	1	4	+	None	OU=PVD	OU	T Glumet,	RBS-251, SCr -1.5 BU-39	HT
52/ M	Laser	26	1	4	+	TRD+ VMT	OS= 360° NVI OD=ERM	OS	T Glucoret Forte, Acarbose	RBS-287, BU-18 ,S SCR-1.00	None
47/ M	None	15	1	4	OD =+	TRD	OD=FVP	OU	T Glycidem, T Isinexex, T Ethanbutol	RBS-251, SCR-1.1. BU 26	HT, DN
53/ M	Laser	20	1	4	OS =+	OS=TRD	OU= NVE,NV D, FVP	OU	T Nalop, T Atorva, T Glycalazide, T Metformin T Asprin	RBS-241. BU 35, SCR-1.1	Hypercholeste rolemia
46/ F	Laser	20	1	4	OD =+	CRD	OS=FVP	OD	T Reclide, T Aztor 10mg.	RBS-231, BU -23,	None

									T Losor H, T Trioptal	SCR-0.9	
68/ M	Laser, AntiVE GF	6 months	1	4	+	OD=CRD	OS=FVP	OD	T Gemet, T Metpure XI, T Atorva. T Olmesar H	RBS-159. BU-38, SCR- 1.1	HT
49/ M	Laser	12	1	4	OD =+	OS=TRD	OU+FVP OD=NVE	OS	T Eslo 5, T Glimi H2 T lipicure	RBS-231, BU-33. SCR-1	HT, DN
54/ M	None	20	2	4	OS =+	OS=TRD	OD=FVP, NVE	OU	TGlyclazide, Bisoprolol, T Orlibose, T Mini Press, T Telvas. T Amlodipine	RBS 152. BU 39, SCR-1.4	None
54/ F	Laser	10	2	4	+	OS= TRD	OD=NVD OU= FVP	OU	Inj Mixtard 12- 0-12, T Atorva, T Rapace, T Glynace MF. T.Stamlo beta	RBS 287, FBS-210, BU-40, SCR- 1.2	HTN, DN, HYPOTHYR OIDISM
48/ F	None	10	2	4	+	None	OS = FVP	OU	T Atocar, T Pyoglit, T Dyotor, T Glynipide T Amtas	BU-51, Scr-1.5. RBS-160	CRF cardiomyopat hy
53/ M	Laser	24	2	4	+	OS = TRD	OS =FVP, TRD OD=CSME	OU	T Glucored, T Envas,	RBS-337, BU-31, SCR-1.1	None

HT, Hypertension; CKD, chronic kidney disease; CRF, chronic renal failure; VEGF: vascular endothelial growth factor; CSME, clinically significant macular edema; TRD, tractional retinal detachment; CRD, combined retinal detachment; NVE, neovascularisation elsewhere; NVI, neovascularization iris; NVD, neovascularization disc; FVP, fibrovascular proliferation; DR, diabetic retinopathy; DN, diabetic nephropathy; VMT, vitreomacular traction; RBS, random blood sugar; SCR, serum creatinine; BU, blood urea.

